Eli Lilly stock has returned roughly 4x over the past five years, yet the current valuation picture is split, with the intrinsic value estimate pointing to meaningful upside while the broader checks suggest the shares are not an obvious bargain.

• Eli Lilly has delivered a very large 5 year return of about 406.7%, which puts extra scrutiny on whether recent gains already reflect the key growth drivers.
• Expectations around new therapies in obesity, neuroscience and oncology can support optimistic cash flow assumptions. However, legal disputes and execution risk on acquisitions such as AtaiBeckley may weigh on how much investors are willing to pay for that growth.
• The Discounted Cash Flow (DCF) work implies the stock trades about 27.9% below intrinsic value. In contrast, Eli Lilly only passes 2 of 6 valuation checks on Simply Wall St, which points to a company that screens as expensive on many metrics despite the DCF upside.

The issue now is whether Eli Lilly's current share price already reflects most of its growth story or still leaves a reasonable margin versus the intrinsic value estimate.

Is Eli Lilly a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Eli Lilly is worth today based on the cash it is expected to generate for shareholders. Eli Lilly currently produces around $8.6b in free cash flow over the latest twelve months, and the DCF uses a growing cash flow path that reaches higher projected levels by 2030.

On this basis, the model points to an intrinsic value of about $1,644 per share. This figure sits above the current share price and implies the stock screens as undervalued by roughly 27.9%. Despite recent headlines around the AtaiBeckley acquisition, the DCF output suggests the market is not fully pricing in the cash flows implied by Eli Lilly’s obesity, neuroscience and oncology pipelines.

Overall, Eli Lilly stock appears undervalued relative to the intrinsic value indicated by the DCF cash flow projections.

Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 27.9%. Track this in your watchlist or portfolio, or discover 38 more high quality undervalued stocks.

Does Eli Lilly Look Fairly Valued on Earnings?

P/E is a useful lens for Eli Lilly because earnings are a central yardstick for established pharmaceuticals. Eli Lilly trades on a P/E of about 41.8x, which is much higher than the Pharmaceuticals industry average of 15.0x and also above the peer group average of 25.5x, so the stock clearly carries a premium to many large drug companies.

The fair P/E ratio implied by the model is 39.2x, which reflects what investors might expect to pay given Eli Lilly’s size, margins, growth profile and risks. The current 41.8x multiple sits only slightly above that fair ratio, suggesting the market is pricing in most of the company’s strengths without stretching too far beyond the model’s benchmark.

Overall, Eli Lilly appears roughly fairly valued on its P/E multiple, trading at only a modest premium to the model’s fair ratio.

The Eli Lilly Narrative: What Would Justify Today's Price?

Simply Wall St Narratives help you connect Eli Lilly's current share price with the assumptions that might sit behind it, by setting out what would need to happen to growth, margins and earnings for the stock to be worth materially more or less than today. Instead of focusing on a single multiple or model, each Narrative lays out the key inputs behind its view of fair value so you can compare those assumptions with Eli Lilly's actual results over time.

The Eli Lilly debate splits sharply between investors who see years of GLP 1 fueled upside and those who think pricing and concentration risks already sit in the share price.

Bull case: roughly fairly valued

"Market penetration for all GLP 1 drugs is only at 4% of a target audience of 100 to 120 million people in the USA alone…"

Bear case: 32% overvalued

"The likelihood of significant drug pricing reforms in the U.S., combined with initiatives to increase pricing parity between the U.S. and Europe, threatens to sharply limit Eli Lilly's future pricing power and compress both future revenue growth and net margins…"

Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!

The Bottom Line

For Eli Lilly, the Discounted Cash Flow (DCF) work points to meaningful intrinsic value upside, while the earnings multiple suggests the stock is priced about right relative to peers. That tension, together with a low broader value check score, suggests the DCF optimism is offset by how much investors already pay for growth using simple ratios. The split largely comes down to whether Eli Lilly can translate its obesity, neuroscience and oncology pipelines into durable cash flows that justify both the DCF upside and the current premium P/E, or whether the market is correctly flagging legal and execution risks as a reason to be cautious on the valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.